Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Overview Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development BrightGene Bio-Medical Technology Co Ltd Celltrion Inc Factor Therapeutics Ltd Merck & Co Inc Pliant Therapeutics Inc SciFluor Life Sciences LLC Tasly Pharmaceutical Group Co Ltd Vascular Pharmaceuticals Inc Virtual Drug Development Inc Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles A-11 - Drug Profile Product Description Mechanism Of Action R&D Progress BGC-0222 - Drug Profile Product Description Mechanism Of Action R&D Progress C-16Y - Drug Profile Product Description Mechanism Of Action R&D Progress cilengitide - Drug Profile Product Description Mechanism Of Action R&D Progress cilengitide - Drug Profile Product Description Mechanism Of Action R&D Progress Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Fusion Protein to Antagonize ITGA5 and ITGB3 for Ischemic Stroke - Drug Profile Product Description Mechanism Of Action R&D Progress MK-0429 - Drug Profile Product Description Mechanism Of Action R&D Progress MSP-68 - Drug Profile Product Description Mechanism Of Action R&D Progress NOD-201 - Drug Profile Product Description Mechanism Of Action R&D Progress OCU-200 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Metastatic Melanoma - Drug Profile Product Description Mechanism Of Action R&D Progress PLN-1177 - Drug Profile Product Description Mechanism Of Action R&D Progress Proagio - Drug Profile Product Description Mechanism Of Action R&D Progress Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress RSF-201 - Drug Profile Product Description Mechanism Of Action R&D Progress RUC-4 - Drug Profile Product Description Mechanism Of Action R&D Progress SF-0166 - Drug Profile Product Description Mechanism Of Action R&D Progress tetraiodothyroacetic acid - Drug Profile Product Description Mechanism Of Action R&D Progress VF-003 - Drug Profile Product Description Mechanism Of Action R&D Progress VF-004 - Drug Profile Product Description Mechanism Of Action R&D Progress VPI-2690B - Drug Profile Product Description Mechanism Of Action R&D Progress xemilofiban - Drug Profile Product Description Mechanism Of Action R&D Progress Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Products Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Product Development Milestones Featured News & Press Releases Dec 04, 2018: Georgia State spinoff gets $2 Million to advance new cancer drug Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases Sep 28, 2017: SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200 Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology Apr 02, 2016: Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200 Jun 30, 2014: VDDI Provides Update On Xemilofiban Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide’s Pivotal Phase III Trial CENTRIC Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indications, H1 2019 Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 (Contd..1), H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by BrightGene Bio-Medical Technology Co Ltd, H1 2019 Pipeline by Celltrion Inc, H1 2019 Pipeline by Factor Therapeutics Ltd, H1 2019 Pipeline by Merck & Co Inc, H1 2019 Pipeline by Pliant Therapeutics Inc, H1 2019 Pipeline by SciFluor Life Sciences LLC, H1 2019 Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019 Pipeline by Vascular Pharmaceuticals Inc, H1 2019 Pipeline by Virtual Drug Development Inc, H1 2019 Dormant Products, H1 2019 Dormant Products, H1 2019 (Contd..1), H1 2019 Dormant Products, H1 2019 (Contd..2), H1 2019 Discontinued Products, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

BrightGene Bio-Medical Technology Co Ltd Celltrion Inc Factor Therapeutics Ltd Merck & Co Inc Pliant Therapeutics Inc SciFluor Life Sciences LLC Tasly Pharmaceutical Group Co Ltd Vascular Pharmaceuticals Inc Virtual Drug Development Inc